ArticleMethodsX2025
An anatomically enhanced and clinically validated framework for lung abnormality classification using deep features and KL divergence.
Article in MethodsX, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Detecting lung abnormalities via chest X-rays is challenging due to understated tissue variations often ignored by traditional methods. Augmentation techniques like rotation or flipping risk distorting critical anatomical features, actually leading to misdiagnosis. This paper proposes a novel two-stage ASCE (Anatomical Segmentation and Color-Based Enhancement) framework for precise and efficient classification of lung abnormalities while preserving anatomical integrity. Stage 1 classifies Normal vs. Pneumonia with 95 % accuracy, an AUC of 0.98, and an F1-score of 0.92. Stage 2 distinguishes Pneumonia into Viral and Bacterial subtypes with 100 % accuracy and F1-score. This approach integrates segmentation and tissue-specific color enhancements with Kullback-Leibler (KL) divergence, quantifying deviations from healthy lung regions for improved classification. The lightweight pipeline ensures computational efficiency (∼0.06s/image) and clinical interpretability by preserving diagnostic features, enhancing visibility, and enabling quantitative analysis.1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.